Axium Healthcare Puerto Rico is Now Dispensing VOXZOGO® and PALYNZIQ®
BioMarin has selected Axium Healthcare as their exclusive Specialty Pharmacy for the Puerto Rico market to dispense VOXZOGO® for the treatment of adult patients with uncontrolled levels of phenylketonuria, and PALYNZIQ® for the treatment that helps increase linear growth in children with achondroplasia.
Axium Healthcare is proud to announce it is now dispensing:
VOXZOGO (vosoritide), for injection use treatment and is indicated:
- is a C type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity.
PALYNZIQ (pegvaliese-pqpz), for injection use treatment and is indicated:
- is a phenylalanine (Phe)-metabolizing enzyme indicated to reduce blood Phe concentrations in adult patients with phenylketonuria who have uncontrolled blood Phe concentrations greater than 600 micromol/L on existing management.
Milton Latoni, VP of Sales & Business Development for Axium Healthcare Puerto Rico, recently shared what access to VOXZOGO and PALYNZIQ means for the rare disease community. “The Rare Disease community in the past few years is benefiting from the latest science developments providing hope due to the lack of treatment options. We are very proud to add both VOXZOGO AND PALYNZIQ to our treatment options for patients with Enzyme Deficiencies.”
At Axium Healthcare our clinical and care teams have extensive experience with the treatment challenges that can arise when dealing with Rare Diseases. We are passionate about simplifying the enrollment process for our patients by providing comprehensive financial services and personalized patient care support.
Axium Healthcare:
At Axium Healthcare, our mission is to be the preferred pharmacy for people undergoing complex medication therapies by optimizing clinical outcomes and providing a high-touch, caring experience. As a leading specialty pharmacy, Axium Healthcare offers comprehensive therapy-management programs as well as injectable and oral pharmaceutical treatments for Dermatology, HIV, Hepatitis C, Oncology, Multiple Sclerosis, Movement Disorders, Rheumatoid Arthritis, Growth Hormone Deficiency, Hunters Syndrome, Hemophilia, IVIG, Rare Diseases plus others. Axium Healthcare services patients island-wide and is ACHC (since 2010) and URAC Accredited (since 2016). Axium Healthcare's clinically effective and cost-efficient therapy management programs provide direct value to healthcare organizations nationwide. We blend a high-touch, caring patient experience with specialized clinical knowledge, personalized care programs, and administrative expertise. For more information, visit www.axiumpr.com.
About BioMarin:
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening genetic diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company's portfolio consists of eight commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. For additional information, please visit www.biomarin.com. www.biomarin.com.
VOXZOGO® and PALYNZIQ® are registered trademarks of BioMarin. Any other trademarks referred to in this release are the property of their respective owners.